Ignite Creation Date:
2025-12-24 @ 1:04 PM
Ignite Modification Date:
2026-01-09 @ 10:39 PM
Study NCT ID:
NCT01784861
Status:
TERMINATED
Last Update Posted:
2021-07-08
First Post:
2013-02-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Sponsor:
Washington University School of Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2020-08-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-08-19
Completion Date Type:
ACTUAL
First Submit Date:
2013-02-04
First Submit QC Date:
None
Study First Post Date:
2013-02-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-05-13
Results First Submit QC Date:
None
Results First Post Date:
2021-06-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-06-15
Last Update Post Date:
2021-07-08
Last Update Post Date Type:
ACTUAL